Mutations in the tyrosine kinase domain of the ROS1 gene are responsible for 43% of ROS1-rearranged NSCLC patients acquiring resistance to lorlatinib [66,137]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.